A Phase 2 interventional study of Quality-of-Life Assessment and Surgical Procedure in Liver and Intrahepatic Bile Duct Neoplasm, Metastatic Malignant Neoplasm in the Liver and Primary Malignant Liver Neoplasm, sponsored by M.D. Anderson Cancer Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by M.D. Anderson Cancer Center · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies in Carcinoma, Hepatocellular by M.D. Anderson Cancer Center — 6 open to participants now, 15 under way, none of them phase 3. Carcinoma, Hepatocellular · M.D. Anderson Cancer Center.
Among the 36 studies in Carcinoma, Hepatocellular by M.D. Anderson Cancer Center, this one is the 5th largest by planned enrollment of the 34 interventional ones that give a count, is one of 6 that started in 2022, is one of 12 in phase 2, reaches primary completion later than 5 of the 14 other live ones, and was the 25th registered.
3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.
Browse Carcinoma, Hepatocellular studies →6 of the 36 studies in Carcinoma, Hepatocellular by M.D. Anderson Cancer Center are open now, in 1 country. Recruiting first, the newest first:
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 19+
M.D. Anderson Cancer Center · Sites in United States
Healthy volunteers
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 16 · Phase 3 1
First in 1998; this study’s year is marked. 6 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 140 is above the median of 53 across 2,623 interventional studies indexed under Carcinoma, Hepatocellular.
Median enrollment 39 across the 34 interventional studies, 285 across the 2 observational. Of the 16 that completed or were terminated, 7 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
M.D. Anderson Cancer Center is the lead sponsor of 3,051 studies on the registry; 580 are open to participants now.
Of its 614 completed or terminated interventional studies of FDA-regulated products, 409 (67%) have results posted.
7 of the studies in Carcinoma, Hepatocellular by M.D. Anderson Cancer Center that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05053555M.D. Anderson Cancer CenterHigh Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies | 2027-01-31 |
| NCT03028311M.D. Anderson Cancer CenterYttrium Y-90 Radioembolization in Treating Patients With Metastatic Liver Cancer | 2027-01-31 |
| NCT04982653M.D. Anderson Cancer CenterShort Stitch Versus Traditional Suture for the Prevention of Incisional Hernia After Open Hepatectomy | 2027-02-02 |
| NCT05143619M.D. Anderson Cancer CenterImpact of "Teaching the Teachers" Concept on Global Education and Application of Hepatocellular Carcinoma Diagnosis Guidelines | 2027-02-02 |
| NCT05394259M.D. Anderson Cancer CenterA Pilot Study to Assess the Clinical Utility of PYLARIFY PET-CT for Detecting Metastasis in Pancreatic Cancer, Hepatocellular Carcinoma and Breast Cancer | 2027-02-02 |
Add all 7 to your calendar (.ics) → With an account.
Among the 36 studies in Carcinoma, Hepatocellular by M.D. Anderson Cancer Center, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This clinical trial compares two different kinds of surgical closing techniques, short stitch suture or traditional suture, in patients who are having liver tumor surgery. This study may help researchers learn if one technique can lower the chances of developing a hole in the wall of the abdomen (an abdominal hernia) at the incision site better than the other.
PRIMARY OBJECTIVE:
I. To assess whether small bites abdominal wall closure reduces the risk of developing incisional hernia following liver surgery.
SECONDARY OBJECTIVES:
I. To compare short-term perioperative outcomes between small bites and typical fascial closure technique.
II. To assess the hernia incidence rate of short stich versus (vs.) standard closure in subgroups of patients with inverted-L or midline incisions.
III. To assess the hernia incidence rate of Kawaguchi-Gayet hepatectomy complexity classifications I/II vs. III (hernia rate by extent of hepatectomy).
IV. To assess the hernia incidence rate of preoperative chemotherapy or no preoperative chemotherapy (hernia rate by exposure to preoperative chemotherapy).
V. To assess impact of small bites abdominal wall closure on health care quality of life following liver surgery.
VI. To assess safety of small tissue bites fascial closure suture technique versus conventional fascial closure following hepatectomy.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I (INTERVENTION): Patients undergo hepatectomy as planned using small bites fascial method for abdominal wall closure.
ARM II (CONTROL): Patients undergo hepatectomy as planned using conventional fascial method for abdominal wall closure.
After completion of study, patients are followed up at 1-4 weeks, and then at 3, 6, and 12 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients undergo hepatectomy as planned using small bites fascial method for abdominal wall closure.
Other: Quality-of-Life Assessment · Procedure: Surgical Procedure
Patients undergo hepatectomy as planned using conventional fascial method for abdominal wall closure.
Other: Quality-of-Life Assessment · Procedure: Surgical Procedure
Ancillary studies
Also known as: Quality of Life Assessment
Undergo hepatectomy using small bites fascial method for abdominal wall closure
Also known as: Operation, Surgery, Surgical, Surgical Intervention, Surgical Interventions, Surgical Procedures, Type of Surgery
Undergo hepatectomy using conventional fascial method for abdominal wall closure
Also known as: Operation, Surgery, Surgical, Surgical Intervention, Surgical Interventions, Surgical Procedures, Type of Surgery
Radiographic incidence rate of incisional hernia
Definition of incisional hernia will be based on the European Hernia Society: Any abdominal wall gap with or without a bulge in the area of a postoperative scar perceptible or palpable by clinical examination or imaging. Assessment of the primary outcome will occur at 3, 6, and 12 months with a computed tomography scan/magnetic resonance imaging. Scans will be read and assessed for incisional hernia by 3 independent assessors blinded to the allocation. A correlation coefficient will be determined for their assessments. The cumulative incidence rate of incisional hernia at 12 months will be estimated, along with the 95% confidence interval.
Time frame: Up to 12 months after surgery
Surgical site infection
Time frame: Up to 90 days after surgery
Surgical site occurrence
Time frame: Up to 90 days after surgery
Surgical site occurrence requiring procedural intervention
Time frame: Up to 90 days after surgery
Postoperative complications
Post-operative infection, complication or pain will be assessed using Chi-squared test or Fisher's exact test.
Time frame: Up to 90 days after surgery
Need for reoperation
Time frame: Up to 90 days after surgery
Need for reoperation secondary to complication of abdominal closure
Time frame: Up to 90 days after surgery
Length of hospital stay (postoperatively)
Will be compared between the two arms using two-sample t-test or Wilcoxon rank sum test.
Time frame: Up to 90 days after surgery
Any readmission related to hernia repair
Time frame: Up to 30 days after surgery
Health-related quality of life assessment
Will use linear mixed effect modeling to assess the effects of time, arm as well as the interaction between arm and time.
Time frame: Up to 12 months after surgery
Incidence of adverse events (AEs)
Will be summarized using descriptive statistics (frequency, percentage) by arm, AE type, severity and attribution.
Time frame: Up to 90 days after surgery
Started Jan 2022 (actual). Primary completion is estimated for Feb 2027, 60 months after the start.
Of 352 non-industry phase 2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 78. This study's planned 60 months is above that.
Counting every sponsor, half of 432 studies reached it within 43 months; a quarter within 30 and three quarters within 71.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.